CClinicalTrials.gg
Not yet recruitingNCT04889456RightUpdated May 17, 2021

Standardizing Right Hemicolectomy for Colon Cancer

An interventional study of Implementation standardised laparoscopic right hemicolectomy with proctoring and Implementation standardised laparoscopic right hemicolectomy without proctoring in Colonic Carcinoma, Laparoscopic Right Hemicolectomy and Standardisation, sponsored by Amsterdam UMC, location VUmc. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-17.

Sponsored by Amsterdam UMC, location VUmc · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2022, 4 years 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
930
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A surgical intervention might be highly variable amongst surgeons and centers. This variability has a potential relevance concerning clinical outcomes.

For right-sided colon cancer, the laparoscopic right hemicolectomy (LRHC) knows substantial variation. Especially since the surgical technique has been evolving during the latest decade with the introduction of intracorporeal anastomosis, a dissection technique within the correct embryological planes (complete mesocolic excision) and central vascular ligation of the segmental branches at its origin, resulting in an optimal lymph node dissection.

Given the insights from recent studies showing the association between quality of surgery and relevant clinical outcomes, there is a great need for a formative quality assessment of LRHC. Detailed objective assessment of the LRHC is currently not performed in clinical practice nor in surgical training. Quality assessment of LRHC has great potential to improve surgical training and furthermore, implementation of a standardized technique will ultimately lead to better quality of care for patients suffering from right-sided colon cancer.

The main objective of this study is to improve surgical outcomes for patient with right-sided colon cancer by a prospective sequential interventional cohort study that aims to standardize the surgical technique with subsequent controlled implementation after standardized review of the current practice in a nationwide multicenter setting. The primary endpoint is the 30-day morbidity according to the Clavien-Dindo classification system.

Read the detailed description
  1. Prospective mapping of current practice with surgical variations in laparoscopic right hemicolectomy (total duration of inclusion 3 months) N= 40 centers N = 310 videos

    1. METC approval for the use of anonymized videos of a laparoscopic procedure and collection of corresponding clinical outcomes.
    2. Approaching hospitals for participation (high volume centers (50+ colon cancers).
    3. Prospective inclusion of consecutive patients undergoing laparoscopic right hemicolectomy in the participating hospitals in three months.
  2. Development of Standard Laparoscopic Right Hemicolectomy: an (inter)national Delphi study

    1. Approaching specialists to participate in the Delphi method (from participating hospitals in step 1).
    2. Identification of crucial steps and measures according to literature and expert's opinion (Delphi method).
    3. Documentation of steps and the order in which they need to be performed, development of a competency assessment tool (CAT).
  3. Skills center training facility

    a. Training the participating surgeons in the method of the standardized laparoscopic right hemicolectomy, as consented in the Delphi method.

  4. Implementation of the standardized laparoscopic right hemicolectomy with proctoring during another period with prospective inclusion of consecutive patients with collection of surgical videos in all participating hospitals (N=40 centers, total 310 videos)

    1. Rating videos.
    2. Comparing with pre-implementation performance based on outcome measures reflecting oncological quality of surgery, and 30-day clinical outcomes.
    3. Comparing with pre-implementation performance based on the long-term outcomes. (3-year DFS and 5-year OS).
  5. Implementing standardised lap right hemicolectomy (after learning curve without proctoring)

    1. Consecutive inclusion of patients (n=310)
    2. CT imaging
    3. Video analysis
    4. Competency analysis
    5. Variation analysis
    6. Clinico pathological data
02

Conditions studied

  • Colonic Carcinoma
  • Laparoscopic Right Hemicolectomy
  • Standardisation
  • Training
  • Delphi Study
  • Implementation
  • Consolidation
  • Assessment

Browse trials for

03

In context

Colonic Neoplasms

1,432 studies on the registry are indexed under Colonic Neoplasms; 357 are open to participants now.

This study's planned enrollment of 930 is above the median of 90 across 1,034 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

Amsterdam UMC, location VUmc is the lead sponsor of 302 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Planned laparoscopic (extended) right hemicolectomy for colon cancer of the caecum, ascending colon or hepatic flexure;
  • Age above 18 years;
  • cTNM stage 1-3 (CT-staged);
  • No prior midline or transverse laparotomy;
  • ASA1-3;
  • No immune modulating medication.

Exclusion criteria

Exclusion Criteria:

  • cT4b;
  • Perforated disease;
  • Acute obstruction;
  • Emergency operation;
  • Appendiceal cancer;
  • Other primary malignancy treated within 5 years from diagnosis of colon cancer, except for curatively treated prostate, breast, skin and cervical cancer.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
930 participants (estimated)

Study arms

  • No intervention
    Surgical variations laparoscopic right hemicolectomy
  • Active comparator
    Implementing standardised laparoscopic right hemicolectomy with proctoring

    Procedure: Implementation standardised laparoscopic right hemicolectomy with proctoring

  • Active comparator
    Implementing standardised laparoscopic right hemicolectomy without proctoring

    Procedure: Implementation standardised laparoscopic right hemicolectomy without proctoring

Interventions

  • ProcedureImplementation standardised laparoscopic right hemicolectomy with proctoring

    Implementation standardised laparoscopic right hemicolectomy with proctoring

  • ProcedureImplementation standardised laparoscopic right hemicolectomy without proctoring

    Implementation standardised laparoscopic right hemicolectomy without proctoring

06

What researchers measure

Primary outcomes

  1. 30-day morbidity with Clavien-Dindo grading

    Time frame: 30 days

Secondary outcomes

  1. Intraoperative complications (i.e. vascular injury)

    Time frame: 1 day

  2. Conversion rate from laparoscopic to open surgery

    Time frame: 1 day

  3. Operative time

    Time frame: 1 day

  4. Blood loss

    Time frame: 1 day

  5. Validated assessment of plane of dissection

    Assessment according to a competency assessment tool (CAT) for laparoscopic right hemicolectomy. This tool will be created during phase 2 using the Delphi method.

    Time frame: 1 day

  6. Validated assessment of level of vascular ligation

    Assessment according to a competency assessment tool (CAT) for laparoscopic right hemicolectomy. This tool will be created during phase 2 using the Delphi method.

    Time frame: 1 day

  7. Grading of the resection specimen according to Benz et al. 2019

    Time frame: 1 day

  8. Total lymph node count

    Time frame: 1 day

  9. Number of resected positive lymph nodes

    Time frame: 1 day

  10. Resection margins

    Radicality of resection margin of the specimen, as assessed by the pathologist.

    Time frame: 1 day

  11. Completeness of mesocolic excision based on postoperative CT imaging

    Time frame: 1 day

  12. Locoregional recurrence

    Time frame: 3 years

  13. Distant metastasis

    Time frame: 3 years

  14. 3-year disease free survival (DFS)

    Time frame: 3 years

  15. 5-year overall survival (OS)

    Time frame: 5 years

  16. Long term morbidity: incisional hernia, adhesion related small bowel obstruction, readmissions, reinterventions

    Time frame: 3 years

07

Study locations

1 site
  • Amsterdam UMC, location VUmc
    Amsterdam, Noord-Holland 1081 HV, Netherlands
    • Alexander A.J. Grüter, MD · Contact · alexandergruter@hotmail.com · +316 45552015
    • Usha K. Coblijn, MD, PhD · Contact · usha.coblijn@gmail.com · +316 43469794
    • Jurriaan B. Tuynman, MD, PhD · Principal investigator
    • Pieter J. Tanis, MD, PhD, Prof · Principal investigator
    • Boudewijn R. Toorenvliet, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04889456
Lead sponsor
Amsterdam UMC, location VUmc
Collaborators
Prof. dr. P.J. Tanis, colorectal surgeon, Dr. B.R. Toorenvliet, colorectal surgeon, D. Miskovic, St Marks hospital London, UK, S. Benz, Klinikverbund SuedWest, Böblingen, Germany, F. Aigner, Krankenhaus der Barmherzigen Bruder, Graz, Austria, C.A. Bertelsen, Hillerød University Hospital, Copenhagen, Denmark, Drs. A.A.J. Grüter, Dr. U.K. Coblijn, Dr. H.L. van Westreenen, Dr. C. Sietses, Prof. dr. E.C.J. Consten, Dr. A.W.H. van de Ven, Dr. P. van Duijvendijk, Dr. S. van Aalten, Dr. F. den Boer, Dr. J.W.A. Leijtens, Dr. C. Hoff, Dr. O. van Ruler, Dr. G. D. Slooter, Prof. dr. J. Lange, Prof. dr. G.J. Kleinrensink
Responsible party
Jurriaan B. Tuynman (Dr, Amsterdam UMC, location VUmc) — Principal investigator
First posted
May 17, 2021
Start date
Jul 1, 2021 (estimated)
Primary completion
Jul 1, 2022 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
May 17, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion